每经AI快讯,复星医药公告,控股子公司浙江星浩澎博医药有限公司于近日收到国家药品监督管理局关于同意XH-S004片用于治疗慢性阻塞性肺疾病的临床试验批准。星浩澎博拟于条件具备后于中国境内(不包括港澳台地区)开展相关临床试验。(文章来源:每日经济新闻)
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.